Natural history and long-term outcome of ulcerative colitis

Journal of Japanese Society of Gastroenterology

Volumn 106, Issue 7, 2009, Pages 969-977

  Matsumoto, Takayuki ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CYCLOSPORIN A; GOLIMUMAB; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; TACROLIMUS;

ARTICLE; DISEASE COURSE; ENTERITIS; HUMAN; PROGNOSIS; ULCERATIVE COLITIS;

EID: 71949102264     PISSN: 04466586     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. Hibi T, Inoue N, Ogata H, et al : Introduction and overview : recent advances in the immunotherapy of inflammatory bowel disease. J Gastroenterol 38 (Suppl) ; 36-112 : 2003 (Pubitemid 36442884)
2. Cantor M, Bernstein CN : Clinical course and natural history of ulcerative colitis. Kirsner's textbook of inflammatory bowel disease. Sartor RB, Sandborn WJ, eds, Edingburgh, 280-288 : 2004
3. Langholz E, Munkholm P, Davidsen M, et al : Course of ulcerative colitis : analysis of changes in disease activity over years. Gastroenterology 107 ; 3-11 : 1994 (Pubitemid 24195339)
4. Hendriksen C, Kreiner S, Binder V : Long term prognosis in ulcerative colitis-based on results from a regional patient group from the county of Copenhagen. Gut 26 ; 158-163 : 1985 (Pubitemid 15105140)
5. Ekbom A, Heimick CG, Zack M, et al : Survival and causes of death in patients with inflammatory bowel disease : a population-based study. Gastroenterology 103 ; 954-960 : 1992
6. Persson PG, Bernell O, Leijonmarck CE, et al : Survival and cause-specific mortality in inflammatory bowel disease : a population-based cohort study. Gastroenterology 110 ; 1339-1345 : 1996 (Pubitemid 26134065)
7. Ekbom A, Helmick C. Zack M, et al : Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med 323 ; 1228-1233 : 1990 (Pubitemid 20366527)
8. Ilnyckyj A, Shanahan F, Anton PA, et al : Quantification of the placebo response in ulcerative colitis. Gastroenterology 112 ; 1854-1858 : 1997
9. Silverstein MD, Loftus EV, Sandborn WJ, et al : Clinical course and costs of care for Crohn's disease : Markov model analysis of a population- based cohort Gastroenterology 117 ; 49-57 : 1999
10. Hiwatashi N, Yamazaki H, Kimura M, et al : Clinical course and long-term prognosis of Japanese patients with ulcerative colitis. Gastroenterol JPN 26 ; 312-318 : 1991
11. Duckley P, Travis S : IBD associated with a stressful life? Inflamm Bowel Dis 14 (Supple) ; S33-S34 : 2008
12. Bitton A, Sewitch MJ, Peppercorn MA, et al : Psychosocial determinants of relapse in ulcerative colitis : a longitudinal study. Am J Gastroenterol 98 ; 2203-2208 : 2003 (Pubitemid 37305360)
13. Hart A, Kamm MA : Review article : mechanism of initiation and perpetuation of gut inflammation by stress. Aliment Pharmacol Ther 16 ; 2017-2028 : 2002 (Pubitemid 36009164)
14. Levenstein S, Prantera C, Varvo V, et al : Stress and exacerbation in ulcerative colitis : a prospective study of patients enrolled in remission. Am J Gastroenterol 95 ; 1213-1220 : 2000 (Pubitemid 30263515)
15. Farmer RG, Easley KA, Rankin GB : Clinical patterns, natural history, and progression of ulcerative colitis. A long-term follow-up of 1116 patients. Dig Dis Sci 38 ; 1137-1146 : 1993
16. Farmer RG, Whelan G, Fazio VW : Long-term follow-up of patients with Crohn's disease. Relationship between the clinical pattern and prognosis. Gastroenterology 88 ; 1818-1825 : 1985
17. Oshitani N, Matsumoto T, Jinno Y, et al : Prediction of short-term outcome for patients with active ulcerative colitis. Dig Dis Sci 45 ; 982-986 : 2000 (Pubitemid 30238262)
18. Mourn B, Ekbom A, Vatn MH, et al : Change in the extent of colonoscopic and histological involvement in ulcerative colitis over time. Am J Gastroenterol 94 ; 1564-1569 : 1999 (Pubitemid 29260447)
19. Leijonmarck CE, Persson PG, Hellers G, et al : Factors affecting colectomy rate in ulcerative colitis : an epidemiologic study. Gut 31 ; 329-333 : 1990 (Pubitemid 20093673)
20. Hendriksen M, Jahensen J, Lygren I, et al : Ulcerative colitis and clinical course : results of a 5- year population-based follow-up study, (the IBSEN study). Inflamm Bowel Dis 12 ; 543-550 : 2006
21. Hendriksen C, Binder V : Social prognosis in patients with ulcerative colitis. Br Med J 281 ; 581-583 : 1980 (Pubitemid 11133941)
22. Kennedy A, Nelson E, Reeves D, et al : A randomized controlled trial to assess the impact of a package comprising a patient-oriented, evidence- based self-help guidebook and patient-centred consultations on disease management and satisfaction in inflammatory bowel disease. Health Technol Assess 7 ; 1-11 : 2003 (Pubitemid 37406762)
23. Blomqvist P, Ekbom A : Inflammatory bowel disease : health care and costs in Sweden in 1994. Scand J Gastroenterol 32 ; 1134-1139 : 1997 (Pubitemid 27523846)
24. Boonen A. Dagnelie PC, Feleus A, et al : The impact of inflammatory bowel disease on labor force participation : results of a population sampled case-control study. Inflamm Bowel Dis 8 ; 382-389 : 2002 (Pubitemid 36411024)
25. Travis S : Inflammatory bowel disease in elderly. Inflammatory Bowel Disease, 4th ed, Satsangi J, Sutherland LR, eds, Churchill Livingstone, London, 729-742 : 2003
26. Rutgeerts P, Vermeire S, Van Assche G : Mucosal healing in inflammatory bowel disease : impossible ideal or therapeutic target? Gut 56 ; 453-455 : 2007
27. Emmrich J, Petermann S, Nowak D, et al : Leukocytapheresis (LCAP) in the management of chronic active ulcerative colitis-results of a randomized pilot trial. Dig Dis Sci 52 ; 2044-2053 : 2007 (Pubitemid 47246519)
28. Frøslie KF, Jahnsen J, Mourn BA, et al : Mucosal healing in inflammatory bowel disease : results from a Norwegian population-based cohort Gastroenterology 133 ; 412-422 : 2007 (Pubitemid 47187355)
29. Cohen JL, Hancock L, Mortensen N, et al : Practice parameters for the surgical treatment of ulcerative colitis. Dis Colon Rectum 48 ; 1997-2009 : 2005
30. Travis SP, Farrant JM, Ricketts C, et al : Predicting outcome in severe ulcerative colitis. Gut 38 ; 905-910 : 1996 (Pubitemid 26231777)
31. Zhang Z, Kennedy H : Ulcerative colitis : current medical therapy and strategies for improving medication adherence. Eur J Gastroenterol Hepatol 21 ; 1-8 : 2009
32. Herrinton LJ, Liu L, Fireman B, et al : Time Trends in Therapies and Outcomes for Adult Inflammatory Bowel Disease. Northern California, 1998-2005. Gastroenterology (Epub) ; 2009
33. Klotz U, Schwab M : Topical delivery of therapeutic agents in the treatment of inflammatory bowel disease. Adv Drug Deliv Rev 57 ; 267-279 : 2005 (Pubitemid 39536102)
34. Hanauer SB : Review article : high-dose aminosalicylates to induce and maintain remissions in ulcerative colitis. Aliment Pharmacol Ther 24 (Suppl) ; 37-40 : 2006
35. Dignass AU, Bokemeyer B, Adamek H, et al : Mesalamine Once Daily Is More Effective Than Twice Daily in Patients With Quiescent Ulcerative Colitis. Clin Gastroenterol Hepatol (Epub) ; 2009
36. Levine JS, Burakoff R : Chemoprophylaxis of colorectal cancer in inflammatory bowel disease : current concepts. Inflamm Bowel Dis 13 ; 1293-1298 : 2007
37. Schwartz M, Cohen R : Optimizing conventional therapy for inflammatory bowel disease. Curr Gastroenterol Rep 10 ; 585-590 : 2008
38. Chopra A, Pardi DS, Loftus EV Jr, et al : Budesonide in the treatment of inflammatory bowel disease : the first year of experience in clinical practice. Inflamm Bowel Dis 12 ; 29-32 : 2006 (Pubitemid 43032448)
39. Hanauer SB : Review article : evolving concepts in treatment and disease modification in ulcerative colitis. Aliment Pharmacol Ther 27 (Suppl) ; 15-21 : 2008
40. Andoh A, Tsujikawa T, Ban H, et al : Monitoring 6-thioguanine nucleotide concentrations in Japanese patients with inflammatory bowel disease. J Gastroenterol Hepatol 23 ; 1373-1377 : 2008
41. Gisbert JP, Linares PM, McNicholl AG, et al : Meta-analysis : efficacy of azathioprine and mercaptopurine in ulcerative colitis. Aliment Pharmacol Ther (Epub) ; 2009
42. Hande S, Wilson-Rich N, Bousvaros A, et al : 5- aminosalicylate therapy is associated with higher 6-thioguanine levels in adults and children with inflammatory bowel disease in remission on 6- mercaptopurine or azathioprine. Inflamm Bowel Dis 12 ; 251-257 : 2006 (Pubitemid 43754643)
43. Maser EA, Deconda D, Lichtiger S, et al : Cyclosporine and infliximab as rescue therapy for each other in patients with steroid-refractory ulcerative colitis. Clin Gastroenterol Hepatol 6 ; 1112-1116 : 2008
44. Ogata H, Matsui T, Nakamura M, et al : A randomised dose finding study of oral tacrolimus (FK 506) therapy in refractory ulcerative colitis. Gut 55 ; 1255-1262 : 2006 (Pubitemid 44277355)
45. Yamamoto S, Nakase H, Mikami S, et al : Long- term effect of tacrolimus therapy in patients with refractory ulcerative colitis. Aliment Pharmacol Ther 28 ; 589-597 : 2008
46. Masunaga Y, Ohno K, Ogawa R, et al : Meta- analysis of risk of malignancy with immunosuppressive drugs in inflammatory bowel disease. Ann Pharmacother 41 ; 21-28 : 2007 (Pubitemid 46145952)
47. Sawada K : Leukocytapheresis as an adjunct to conventional medication for inflammatory bowel disease. Dis Colon Rectum 46 (10 Suppl) ; S66-77 : 2003
48. Hibi T, Sameshima Y. Sekiguchi Y, et al : Treating ulcerative colitis by Adacolumn therapeutic leucocytapheresis : Clinical efficacy and safety based on surveillance of 656 patients in 53 centres in Japan. Dig Liver Dis (Epub) ; 2009
49. Matsumoto T, Andoh A, Okawa K, et al : Multivariate analysis for factors predicting rapid response of leukocytapheresis in patients with steroid-resistant ulcerative colitis : a multicenter prospective open-label study. Ther Apher Dial 12 ; 484-490 : 2008
50. Sands BE, Sandborn WJ, Feagan B, et al : A randomized, double-blind, sham-controlled study of granulocyte/monocyte apheresis for active ulcerative colitis. Gastroenterology 135 ; 400--409 : 2008
51. Saniabadi AR, Hanai H, Fukunaga K, et al : Therapeutic leukocytapheresis for inflammatory bowel disease. Transfus Apher Sci 37 ; 191-200 : 2007 (Pubitemid 350186259)
52. Maiden L, Takeuchi K, Baur R, et al : Selective white cell apheresis reduces relapse rates in patients with IBD at significant risk of clinical relapse. Inflamm Bowel Dis 14 ; 1413-1418 : 2008
53. Targan SR, Hanauer SB, van Deventer SJ, et al : A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 337 ; 1029-1035 : 1997
54. Rutgeerts P, Sandborn WJ, Feagan BG, et al : Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353 ; 2462-2476 : 2005 (Pubitemid 41565956)
55. Afif W, Leighton JA, Hanauer SB, et al : Open- label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab. Inflamm Bowel Dis (Epub) ; 2009
56. Eaden JA, Abrams KR, Mayberry JF : The risk of colorectal cancer in ulcerative colitis : a meta- analysis. Gut 48 ; 526-535 : 2001
57. Matsumoto T, Iwao Y, Igarashi M, et al : Endoscopic and chromoendoscopic atlas featuring dysplastic lesions in surveillance colonoscopy for patients with long-standing ulcerative colitis. Inflamm Bowel Dis 14 ; 259-264 : 2008 (Pubitemid 351288049)